siRNA


Also found in: Acronyms, Wikipedia.

siRNA

siRNA

short, interfering ribonucleic acid.

siRNA

abbrev. SHORT INTERFERING RNA
References in periodicals archive ?
It has demonstrated that Sirnaomics team is able to build platforms achieving preclinical study success and overcoming the regulatory hurdles in both countries, for discovery and development of novel siRNA therapeutics, said the Chairman of the board of Suzhou Sirnaomics, Dr.
This is mediated by small RNA comprised of 21-23 nucleotides length termed siRNA, specifically directing cleavage of complementary mRNA targets in a procedure that is commonly considered to be an antiviral cellular defense mechanism.
Altogen Labs is unique in that it offers a comprehensive host of RNAi services (among many other preclinical biology lab services) including RNAi gene targeting, siRNA synthesis, functional in vitro validation via qPCR and Western Blot, siRNA encapsulation, in vivo siRNA protection and tissue-targeted delivery.
The results demonstrated that cells treated with three different sequences of siRNA had a five-fold drop in the amount of infected cells evaluated by direct immunofluorescence test when compared to controls, with no cytopathogenicity due to the treatment.
Because of the predictability of RNAi based on its matching target sequence [2, 5, 7, 9-11, 14, 15, 19, 22, 25, 26], quite a few studies have been devoted to computer-guided algorithms to design effective siRNA or shRNA (from here on, this article will only refer to siRNA for simplicity) [4, 6, 12, 15, 20, 25, 26], However, a critical requirement in siRNA design is to guarantee that the designed siRNA is free of off-target effect.
Using an siRNA dose 10-100-fold lower than previous studies, the research team efficiently silenced the expression of PHD2-a protein that normally inhibits blood vessel formation- locally within a biodegradable tissue scaffold.
Reynolds et al, Uitei et al, Amarzguioui and Prydz mostly emphasized on position preferences in siRNA sequence (15), (19), (21-23).
A current challenge to using siRNA to block growth of cancerous tumors or guide cell behavior in tissue engineering, is that the tiny material rapidly disperses when injected in the bloodstream or directly into target tissues.
0 cells with individual siRNA specific targeting p15 and found that transfection with the Y3 siRNA inhibited the p15 expression in a dose and time-dependent manner in vitro.
The target sequences in the CYP19 gene used for siRNA designing (acc.
The challenges of systemic siRNA delivery are well documented and include numerous biological barriers that limit RNAi therapeutics' ability to reach targets safely and effectively.
As Intradigm's first issued piece of intellectual property (IP) related to an active pharmaceutical ingredient, this patent supplements the company's existing patent portfolio, providing Intradigm issued IP in each of the three essential areas of RNAi therapeutic development: target sequences, delivery and siRNA structural features.